Uterine fibroids are non-cancerous tumors that grow in or on a woman's uterus. Symptoms caused by fibroids vary in severity and include heavy or painful periods, pressure or pain in the lower abdomen, frequent urination, etc. Over-the-counter medications like ibuprofen can help relieve symptoms but do not address the underlying cause. Surgical procedures are an option but carry risks. Therefore, drug therapies that can shrink or eliminate fibroids without surgery present an attractive option for many patients. The global uterine fibroids treatment drugs market offers promising growth opportunities as researchers work to develop novel therapies.
Market Dynamics:
The growing prevalence of uterine fibroids among women coupled with the demand for non-invasive treatment options is a key factor fueling the uterine fibroids treatment drugs market growth. As per Office on Women's Health press release published in February 2021, around 20-80% women develop fibroids by the age of 50. Moreover, the limitations and risks associated with surgical procedures are further driving research into pharmaceutical therapies. However, the high costs involved in drug development pose a challenge. Additionally, lack of awareness about fibroid treatment options in developing nations also restrains market expansion. Meanwhile, emerging oral therapies in the clinical trial pipeline are expected to provide new opportunities.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook